1
|
Seytre B, Yoro B, Djedou M, Madiarra O, Mamey K, Diabagate A, Kouamé K, Simaga F. [HIV communication paradigms must be changed in Africa]. Med Trop Sante Int 2021; 1:JNZG-J383. [PMID: 35685399 PMCID: PMC9128461 DOI: 10.48327/jnzg-j383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
We conducted a socio-anthropological study in Ivory Coast to determine recommendations for a communication strategy aimed at increasing HIV testing, especially among young men. The study results showed that the existence of HIV testing is widely known as are the reasons for getting tested. Fear of death and of stigmatization is the main obstacle to testing. Men are more likely than women to be reluctant to undergo HIV testing, and the fear of dying of AIDS is especially strong among young people. Perceptions of HIV treatments are contradictory: while most of those interviewed know about HIV treatments and say that treatment makes it possible to maintain good health, HIV infection is still frequently associated with death. We recommend reinitiating the mass communication campaign around HIV that was abandoned in order to focus on targeted programs, in order to change perceptions of HIV infection and encourage people who are sexually active to get tested, especially those practicing risky behaviors. We also recommend developing communication messages targeting young men.
Collapse
Affiliation(s)
- B. Seytre
- bnscommunication, 7 rue Ledion, 75014 Paris, France
| | - B.M. Yoro
- Université Félix Houphouët Boigny, Abidjan, Côte d’Ivoire
| | - M.A. Djedou
- Université Peleforo Gon Coulibaly, Korhogo, Côte d’Ivoire
| | | | - K. Mamey
- Alliance, Abidjan, Côte d’Ivoire
| | | | | | | |
Collapse
|
2
|
Borcoman E, Ngo C, Rapinat A, Simaga F, Mariani O, Fuhrmann L, Jeannot E, Laé M, Pierga JY, Gentien D, Pierron G, Morel P, Brauer HA, Vincent-Salomon A. Abstract P6-17-25: PAM50 and CGH-array genomic characterization of HER2-equivocal breast cancers defined by the ASCO/CAP2013 recommendations and response to treatment. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-17-25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
HER2 breast cancer status determines patients' eligibility for targeted therapy. HER2 level of amplification is associated with a better response to anti-HER2 therapy (Arnould CCR 2007, Singer CCR 2017). Benefit of anti-HER2 therapy for equivocal cases remains debated.
Objectives
We aimed to better characterize HER2-equivocal breast cancers by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) according to 2013 ASCO/CAP guidelines using PAM50 gene expression-based molecular subtyping. We then investigated genome-wide copy number alterations of HER2-equivocal cases, assessing agreement between genomic alterations of the chromosome (chr) 17 and molecular subtypes.
Methods
PAM50 (nCounter assay; Nanostring) was performed on RNA from formalin-fixed paraffin-embedded samples of 40 HER2-equivocal cases. These cases were subsequently analyzed by Agilent 60-mer oligonucleotide microarrays for array-based comparative genomic hybridization (aCGH).
Results
The 40 HER2-equivocal cases were classified as Luminal B in 16 cases (40%), HER2-Enriched in 14 cases (35%), Luminal A in 9 cases (22.5%) and Basal-like in 1 case (2.5%) using PAM50.
By IHC, 34 cases (85%) were ER+, 24 (60%) were also PgR+, 26 (65%) were grade III and 33 (82.5%) showed a high Ki67 > 20%.
Using aCGH, 10 cases (25%) presented chr 17q large copy number gain, 10 (25%) showed segmental copy number gains including HER2, 9 (22.5%) showed HER2 amplification, one (2.5%) showed a large copy number loss and 10 cases (25%) didn't show any copy number alteration of the chr 17.
Out of the 14 PAM50 HER2-Enriched cases, only 5 (35.7%) showed HER2 genomic amplification (Table 1). Four HER2 amplified cases at the genomic level were classified as Luminal B (3 cases, Ki67 > 20%, ER+, PgR- by IHC) or Luminal A (1 case, Ki67<20%, ER+, PgR>10% by IHC) using PAM50, although these luminal B tumors presented strong correlation with the HER2-Enriched centroid. In total, 13 cases (32.5%) were discordant between molecular classification and genomic alteration status of the chr 17.
Among patients with early stage HER2-equivocal breast cancers (n=37), 2 received neo-adjuvant chemotherapy (5.4%), 25 received adjuvant chemotherapy (67.6%) and 2 received adjuvant trastuzumab (5.4%). With a median follow up of 5.8 years (3.8-6.9), one controlateral recurrence (2.7%), four metastatic recurrences (10.8%) and three deaths were observed (8.1%).
Conclusion
Using PAM50, the majority of HER2-equivocal cases were classified as Luminal tumors.
At the genomic level, HER2-equivocal cases harbored mostly chr 17 segmental or large copy number gains. These results emphasized the need of HER2 status genomic determination. In line with the new ASCO 2018 recommendations intending to decrease the number of cases considered as HER2 equivocal, we showed that these tumors were mainly HER2 not amplified, ER positive and grade 3. There is no evidence of benefit of anti-HER2 therapy in these cases.
Table 1Genomic alterations of chromosome 17Basal-likeHER2-EnrichedLuminal ALuminal BTotalHER2 amplified05139Large copy number gain013610Segmental copy number gain153110No alteration032510Large copy number loss00011Total11491640
Citation Format: Borcoman E, Ngo C, Rapinat A, Simaga F, Mariani O, Fuhrmann L, Jeannot E, Laé M, Pierga J-Y, Gentien D, Pierron G, Morel P, Brauer HA, Vincent-Salomon A. PAM50 and CGH-array genomic characterization of HER2-equivocal breast cancers defined by the ASCO/CAP2013 recommendations and response to treatment [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-25.
Collapse
Affiliation(s)
- E Borcoman
- Institut Curie, Paris, Ile de France, France; Nanostring Technologies, Seattle, WA
| | - C Ngo
- Institut Curie, Paris, Ile de France, France; Nanostring Technologies, Seattle, WA
| | - A Rapinat
- Institut Curie, Paris, Ile de France, France; Nanostring Technologies, Seattle, WA
| | - F Simaga
- Institut Curie, Paris, Ile de France, France; Nanostring Technologies, Seattle, WA
| | - O Mariani
- Institut Curie, Paris, Ile de France, France; Nanostring Technologies, Seattle, WA
| | - L Fuhrmann
- Institut Curie, Paris, Ile de France, France; Nanostring Technologies, Seattle, WA
| | - E Jeannot
- Institut Curie, Paris, Ile de France, France; Nanostring Technologies, Seattle, WA
| | - M Laé
- Institut Curie, Paris, Ile de France, France; Nanostring Technologies, Seattle, WA
| | - J-Y Pierga
- Institut Curie, Paris, Ile de France, France; Nanostring Technologies, Seattle, WA
| | - D Gentien
- Institut Curie, Paris, Ile de France, France; Nanostring Technologies, Seattle, WA
| | - G Pierron
- Institut Curie, Paris, Ile de France, France; Nanostring Technologies, Seattle, WA
| | - P Morel
- Institut Curie, Paris, Ile de France, France; Nanostring Technologies, Seattle, WA
| | - HA Brauer
- Institut Curie, Paris, Ile de France, France; Nanostring Technologies, Seattle, WA
| | - A Vincent-Salomon
- Institut Curie, Paris, Ile de France, France; Nanostring Technologies, Seattle, WA
| |
Collapse
|
3
|
Ngo C, Borcoman E, Simaga F, Mariani O, Fuhrmann L, Jeannot E, Loirat D, Lae M, Pierga JY, Pierron G, Vincent-Salomon A. Abstract P2-05-11: Not presented. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-05-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- C Ngo
- Institut Curie, Paris, France
| | | | | | | | | | | | | | - M Lae
- Institut Curie, Paris, France
| | | | | | | |
Collapse
|
5
|
Sall ND, Sall PL, Diallo F, Moreira C, Diatta A, Sarr NG, Simaga F, Toure M, Faye B, Fall M. [Protein profile of Senegalese children presenting with nephrotic syndrome]. Dakar Med 2000; 45:77-80. [PMID: 14666797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
In Senegal, nephrotic syndrome usually occurs upon malnutrition that confers it its specificity and has brought us to establish the proteinic profile of Senegalese children suffering from it, in the aim to improve its treatment. Twenty children on the average of six years, hospitalized for nephrotic syndrome, were chosen. They were compared to 20 healthy children of the same age group, and 20 other children hospitalized for a non-renal inflammatory syndrome. For each subject were dosed total blood proteins and albumin. The protein electrophoresis has permitted to evaluate the alpha-1, alpha-2, beta and gamma globulins. We have observed predominance of boys with a 2.33 sex ratio. Our patients presenting a nephrotic syndrome were about six years old; no case has been noted before two years. Total proteins and albumin have decreased respectively to 52.10 g/l and 16 g/l. This diminishing is essentially linked to the massive urinary escape of plasmatic proteins and would explain partly the increase of lipids. The alpha-1 globulins were equally lowered but the alpha-2 globulins were increased by 40% of total proteins. Beta globulins have decreased, following the evolution of gamma globulins. In Senegal, The early age of nephrotic syndrome occurrence and the biological perturbations of the proteinic profile, recommend global and quick treatment considering food recovery and nutrition. The correction of these parameters being able to constitute in one hand an element of accessible and reliable supervision, and one the other hand the basis of complete treatment.
Collapse
Affiliation(s)
- N D Sall
- Laboratoire de Biochimie Médicale, Faculté de Médecine et de Pharmacie-UCAD-Dakar
| | | | | | | | | | | | | | | | | | | |
Collapse
|